New research indicates that patients who come off new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who end conventional diet and exercise regimens.
Findings released in a major medical journal shows that while overweight people frequently drop about a fifth of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users using these medications must be aware of the risk of quick weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass within about one and a half years.
Weighing Therapies
The study, which reviewed 37 of studies involving thousands of participants, compared the results of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone typically see a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Nutrition scientists believe the mode of action of the drugs explains the heightened regain.
These medications mimic a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, considering the likelihood of weight regain, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "highlight the chronic nature of obesity," akin to managing diseases like high blood pressure.
User Experiences
Individuals who have stopped the jabs report a sudden resurgence of hunger.
"It felt as if a switch that goes on and I was suddenly extremely hungry," described one woman.
The struggle is worsened if individuals have not adopted lasting dietary or behavioural changes during therapy.
Widespread Interest
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a standalone cure and lasting health benefits relies on integrated lifestyle support.
